Australian researchers reported a molecular vulnerability that may help explain the spread of triple-negative breast cancer, and they described how an existing drug could potentially be repurposed against it. The work centers on a regulatory system tied to TNBC progression that researchers at the Adelaide University and the Olivia Newton-John Cancer Research Institute linked to metastatic behavior. The finding adds a new mechanistic angle for drug discovery in a subtype where target availability has been limited. It also highlights the translational opportunity created when a discrete regulatory vulnerability is mapped to an actionable pathway.